These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 30240132)

  • 1. Pharmacokinetics and Safety of CSL112 (Apolipoprotein A-I [Human]) in Adults With Moderate Renal Impairment and Normal Renal Function.
    Tortorici MA; Duffy D; Evans R; Feaster J; Gille A; Mant TGK; Wright SD; D'Andrea D
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):628-636. PubMed ID: 30240132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Moderate Renal Impairment Does Not Impact the Ability of CSL112 (Apolipoprotein A-I [Human]) to Enhance Cholesterol Efflux Capacity.
    Gille A; Duffy D; Tortorici MA; Wright SD; Deckelbaum LI; D'Andrea DM
    J Clin Pharmacol; 2019 Mar; 59(3):427-436. PubMed ID: 30452776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The CSL112-2001 trial: Safety and tolerability of multiple doses of CSL112 (apolipoprotein A-I [human]), an intravenous formulation of plasma-derived apolipoprotein A-I, among subjects with moderate renal impairment after acute myocardial infarction.
    Gibson CM; Kerneis M; Yee MK; Daaboul Y; Korjian S; Mehr AP; Tricoci P; Alexander JH; Kastelein JJP; Mehran R; Bode C; Lewis BS; Mehta R; Duffy D; Feaster J; Halabi M; Angiolillo DJ; Duerschmied D; Ophuis TO; Merkely B
    Am Heart J; 2019 Feb; 208():81-90. PubMed ID: 30580130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Apolipoprotein A-I, After Acute Myocardial Infarction: The AEGIS-I Trial (ApoA-I Event Reducing in Ischemic Syndromes I).
    Michael Gibson C; Korjian S; Tricoci P; Daaboul Y; Yee M; Jain P; Alexander JH; Steg PG; Lincoff AM; Kastelein JJ; Mehran R; D'Andrea DM; Deckelbaum LI; Merkely B; Zarebinski M; Ophuis TO; Harrington RA
    Circulation; 2016 Dec; 134(24):1918-1930. PubMed ID: 27881559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.
    Tricoci P; D'Andrea DM; Gurbel PA; Yao Z; Cuchel M; Winston B; Schott R; Weiss R; Blazing MA; Cannon L; Bailey A; Angiolillo DJ; Gille A; Shear CL; Wright SD; Alexander JH
    J Am Heart Assoc; 2015 Aug; 4(8):e002171. PubMed ID: 26307570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSL112 (Apolipoprotein A-I [Human]) Strongly Enhances Plasma Apoa-I and Cholesterol Efflux Capacity in Post-Acute Myocardial Infarction Patients: A PK/PD Substudy of the AEGIS-I Trial.
    Gibson CM; Kazmi SHA; Korjian S; Chi G; Phillips AT; Montazerin SM; Duffy D; Zheng B; Heise M; Liss C; Deckelbaum LI; Wright SD; Gille A
    J Cardiovasc Pharmacol Ther; 2022; 27():10742484221121507. PubMed ID: 36282079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multiple ascending dose study of CSL112, an infused formulation of ApoA-I.
    Easton R; Gille A; D'Andrea D; Davis R; Wright SD; Shear C
    J Clin Pharmacol; 2014 Mar; 54(3):301-10. PubMed ID: 24122814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction.
    Gibson CM; Korjian S; Tricoci P; Daaboul Y; Alexander JH; Steg PG; Lincoff AM; Kastelein JJ; Mehran R; D'Andrea D; Merkely B; Zarebinski M; Ophius TO; Harrington RA
    Am Heart J; 2016 Oct; 180():22-8. PubMed ID: 27659879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of CSL112 (apolipoprotein A-I [human]) on cholesterol efflux capacity in Japanese subjects: Findings from a phase I study and a cross-study comparison.
    Zheng B; Goto S; Clementi R; Feaster J; Duffy D; Dalitz P; Airey J; Korjian S; Tortorici MA; Roberts J; Gibson CM
    Clin Transl Sci; 2022 Oct; 15(10):2331-2341. PubMed ID: 35933730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CSL112 (Apolipoprotein A-I [Human]) Enhances Cholesterol Efflux Similarly in Healthy Individuals and Stable Atherosclerotic Disease Patients.
    Gille A; D'Andrea D; Tortorici MA; Hartel G; Wright SD
    Arterioscler Thromb Vasc Biol; 2018 Apr; 38(4):953-963. PubMed ID: 29437574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacometric analyses to characterize the effect of CSL112 on apolipoprotein A-I and cholesterol efflux capacity in acute myocardial infarction patients.
    Zheng B; Duffy D; Tricoci P; Kastrissios H; Pfister M; Wright SD; Gille A; Tortorici MA
    Br J Clin Pharmacol; 2021 Jun; 87(6):2558-2571. PubMed ID: 33217027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects.
    Gille A; Easton R; D'Andrea D; Wright SD; Shear CL
    Arterioscler Thromb Vasc Biol; 2014 Sep; 34(9):2106-14. PubMed ID: 24969776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI.
    Povsic TJ; Korjian S; Bahit MC; Chi G; Duffy D; Alexander JH; Vinereanu D; Tricoci P; Mears SJ; Deckelbaum LI; Bonaca M; Ridker PM; Goodman SG; Cornel JH; Lewis BS; Parkhomenko A; Lopes RD; Aylward P; Lincoff AM; Heise M; Sacks F; Nicolau JC; Merkely B; Trebacz J; Libby P; Nicholls SJ; Pocock S; Bhatt DL; Kastelein J; Bode C; Mahaffey KW; Steg PG; Tendera M; Bainey KR; Harrington RA; Mehran R; Duerschmied D; Kingwell BA; Gibson CM;
    J Am Coll Cardiol; 2024 Jun; 83(22):2163-2174. PubMed ID: 38588930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apolipoprotein A1 Infusions and Cardiovascular Outcomes after Acute Myocardial Infarction.
    Gibson CM; Duffy D; Korjian S; Bahit MC; Chi G; Alexander JH; Lincoff AM; Heise M; Tricoci P; Deckelbaum LI; Mears SJ; Nicolau JC; Lopes RD; Merkely B; Lewis BS; Cornel JH; Trebacz J; Parkhomenko A; Libby P; Sacks FM; Povsic TJ; Bonaca M; Goodman SG; Bhatt DL; Tendera M; Steg PG; Ridker PM; Aylward P; Kastelein JJP; Bode C; Mahaffey KW; Nicholls SJ; Pocock SJ; Mehran R; Harrington RA;
    N Engl J Med; 2024 May; 390(17):1560-1571. PubMed ID: 38587254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSL112, a reconstituted, infusible, plasma-derived apolipoprotein A-I: safety and tolerability profiles and implications for management in patients with myocardial infarction.
    Capodanno D; Mehran R; Gibson CM; Angiolillo DJ
    Expert Opin Investig Drugs; 2018 Dec; 27(12):997-1005. PubMed ID: 30376729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and design of ApoA-I Event Reducing in Ischemic Syndromes II (AEGIS-II): A phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group study to investigate the efficacy and safety of CSL112 in subjects after acute myocardial infarction.
    Gibson CM; Kastelein JJP; Phillips AT; Aylward PE; Yee MK; Tendera M; Nicholls SJ; Pocock S; Goodman SG; Alexander JH; Lincoff AM; Bode C; Duffy D; Heise M; Berman G; Mears SJ; Tricoci P; Deckelbaum LI; Steg PG; Ridker P; Mehran R
    Am Heart J; 2021 Jan; 231():121-127. PubMed ID: 33065120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel formulation of a reconstituted high-density lipoprotein (CSL112) dramatically enhances ABCA1-dependent cholesterol efflux.
    Diditchenko S; Gille A; Pragst I; Stadler D; Waelchli M; Hamilton R; Leis A; Wright SD
    Arterioscler Thromb Vasc Biol; 2013 Sep; 33(9):2202-11. PubMed ID: 23868939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of potential antiplatelet effects of CSL112 (Apolipoprotein A-I [Human]) in patients with atherosclerosis: results from a phase 2a study.
    Gurbel PA; Tantry US; D'Andrea D; Chung T; Alexander JH; Bliden KP; Wright SD; Tricoci P
    J Thromb Thrombolysis; 2018 May; 45(4):469-476. PubMed ID: 29582212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study.
    Kim S; Lee J; Shin D; Lim KS; Kim YS; Jang IJ; Yu KS
    Drug Des Devel Ther; 2014; 8():1723-31. PubMed ID: 25336916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological basis and proposed mechanism of action of CSL112 (apolipoprotein A-I [human]) for prevention of major adverse cardiovascular events in patients with myocardial infarction.
    Korjian S; Kazmi SHA; Chi G; Kalayci A; Lee JJ; Talib U; Wright SD; Duffy D; Kingwell BA; Mehran R; Ridker PM; Gibson CM
    Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):387-398. PubMed ID: 36787889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.